

Date: July 27, 2026

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Sub.: Submission of statement of Deviation or Variation in utilisation of funds of public issue for quarter ended on June 30, 2026

Dear Sir/Madam,

Pursuant to Regulation 32 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular no. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024 and SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFDPD2/I/3762/2026 dated January 30, 2026, please find enclosed herewith the statement of deviation(s) or variation(s) in utilisation of funds raised through Initial Public Offer ("IPO") by the Company for the quarter ended June 30, 2026.

We hereby confirm that there has been no deviation(s) or variation(s) in the utilization of proceeds of IPO for the abovementioned period as mentioned in the objects stated in the Prospectus dated December 24, 2024.

The aforesaid statement has been reviewed by the Audit Committee and taken on record by the Board of Directors at their respective meetings held on July 27, 2026.

This intimation is also being uploaded on the website of the Company i.e. www.senorespharma.com.

You are requested to take the same on record.

Thanking you.

For Senores Pharmaceuticals Limited

Deval Rajnikant Shah
Whole Time Director & CFO
DIN: 00332722

Enclosure: As above

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com
W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

**STATEMENT OF DEVIATION(S) / VARIATION(S) IN UTILISATION OF FUNDS RAISED THROUGH
IPO, FOR THE QUARTER ENDED JUNE 30, 2026**

Name of listed entity	Senores Pharmaceuticals Limited
Mode of Fund Raising	Initial Public offer
Date of Raising Funds	December 26, 2024
Amount Raised	Rs. 500 Crores
Report filed for Quarter ended	June 30, 2026
Monitoring Agency	Applicable
Monitoring Agency Name, if applicable	CARE Ratings Limited
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable
If Yes, Date of shareholder Approval	Not Applicable
Explanation for the Deviation / Variation	Not Applicable
Comments of the Audit Committee after review	No comments
Comments of the auditors, if any	No comments

(₹ in Crores)

Objects for which funds have been raised and where there has been a deviation, in the following table						
Original Object	Modified Object, if any	Original Allocation	Modified Allocation, if any	Funds Utilized	Amount of Deviation/ Variation for the quarter according to applicable object	Remarks, if any
Investment in one of our Subsidiaries, Havix, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility	Not Applicable	107.00	Not Applicable	6.98	Not Applicable	There is on-going delay in deployment of funds under object-1. Now, the company has sought shareholder approval for variation in the objects /

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

						terms of utilisation of IPO proceeds and extension of time limit through postal ballot.
Re-payment/pre-payment, in full or in part, of certain borrowings availed by our Company	Not Applicable	73.48	73.10	73.10	Not Applicable	The unutilized amount of Rs. 0.38 crore has been transferred to GCP as resolved in the Board Meeting dated July 23, 2025.
Investment in our Subsidiary, namely, Havix, for re-payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiaries	Not Applicable	20.22	20.20	20.20	Not Applicable	The unutilized amount of Rs. 0.02 crore has been transferred to GCP as resolved in the Board Meeting dated July 23, 2025.
Funding the working capital requirements of our Company	Not Applicable	43.26	Not Applicable	43.26	Not Applicable	-
Investment in our Subsidiaries, namely, SPI and Ratnatris to fund their working capital requirements	Not Applicable	59.48	Not Applicable	59.48	Not Applicable	-
Funding inorganic growth through acquisition and	Not Applicable	154.37	161.91	161.63	Not Applicable	Amount of Rs. 7.54 crore has been

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
 Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

other strategic initiatives and general corporate purposes						transferred from Objective 2, 3 and 7.
Offer expenses	Not Applicable	42.19	35.04	34.80	Not Applicable	The unutilized amount of Rs. 6.31 crore under objective-7 has been transferred to objective-6 as resolved in the Board Meeting dt. March 28, 2026 and Rs. 0.84 crore as resolved in Board Meeting dt. May 14, 2026
Total		500.00		399.46		

Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which the funds have been raised; or
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed; or
- (c) Change in terms of a contract referred to in the fund-raising documents i.e, prospectus, letter of offer, etc

For Senores Pharmaceuticals Limited

Deval Rajnikant Shah

Whole Time Director & CFO

DIN: 00332722

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
 Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263